

КЛІНІЧНА АНАТОМІЯ ТА ОПЕРАТИВНА ХІРУРГІЯ

Том 22, № 2 (82)
2023

Науково-практичний медичний журнал
Видається 4 рази на рік
Заснований в квітні 2002 року

Головний редактор
Слободян О.М.

Почесний головний редактор
Ахтемійчук Ю.Т.

**Перший заступник
головного редактора**
Іващук О.І.

**Заступник головного
редактора**
Ковальчук О.І.

Відповідальні секретарі
Товкач Ю.В.
Бойчук О.М.

Секретар
Лаврів Л.П.

Редакційна колегія

Андрієць О.А.

Бербець А.М.

Білоокий В.В.

Боднар О.Б.

Булик Р.Є.

Давиденко І.С.

Максим'юк В.В.

Олійник І.Ю.

Польовий В.П.

Проняєв Д.В.

Сидорчук Р.І.

Хмара Т.В.

Цигикало О.В.

Юзько О.М.

Засновник і видавець: Буковинський державний медичний університет МОЗ України
Адреса редакції: 58002, пл. Театральна, 2, Чернівці, Україна

URL: <http://kaos.bsmu.edu.ua/>;
E-mail: cas@bsmu.edu.ua

РЕДАКЦІЙНА РАДА

Білаш С. М. (Полтава), Бойко В. В. (Харків), Вансович В. Є. (Одеса), Вовк О. Ю. (Харків), Гнатюк М. С. (Тернопіль), Головацький А. С. (Ужгород), Гумінський Ю. Й. (Вінниця), Гунас І. В. (Вінниця), Дзюбановський І. Я. (Тернопіль), Каніковський О. Є. (Вінниця), Катеренюк І. М. (Кишинів, Молдова), Кошарний В. В. (Дніпро), Кривко Ю. Я. (Львів), Ляховський В. І. (Полтава), Масна З. З. (Львів), Матешук-Вацеба Л.Р. (Львів), Небесна З. М. (Тернопіль), Пархоменко К. Ю. (Харків), Пастухова В. А. (Київ), Півторак В. І. (Вінниця), Пикалюк В. С. (Луцьк), Попадинець О. Г. (Івано-Франківськ), Россі П. (Рим, Італія), Савва А. (Яси, Румунія), Салютін Р. В. (Київ), Сікора В. З. (Суми), Суман С. П. (Кишинів, Молдова), Топор Б. М. (Кишинів, Молдова), Трофімов М. В. (Дніпро), Федонюк Л. Я. (Тернопіль), Філіпоу Ф. (Бухарест, Румунія), Чемерис О. М. (Львів), Черно В. С. (Миколаїв), Шаповал С. Д. (Запоріжжя), Шепітько В. І. (Полтава), Шкарбан В. П. (Київ).

EDITORIAL COUNCIL

Anca Sava (Yassy, Romania), Boyko V. V. (Kharkiv), Chemeris O. M. (Lviv), Dzyubanovsky I. Ya. (Ternopil), Florin Filipoiu (Bucureshti, Romania), Pellegrino Rossi (Roma, Italy), Suman Serghei (Kishinev, Moldova), Bilash S.M (Poltava), Vovk O. Yu. (Kharkiv), Gnatyuk MS (Ternopil), Golovatsky A. C. (Uzhgorod), Guminsky Yu. Y. (Vinnitsa), Gunas I. V. (Vinnytsya), Kanikovsky O. Ye. (Vinnytsia), Kateryenyuk I. M. (Kishinev, Moldova), Kosharnyi V. V. (Dnipro), Krivko Yu. Ya. (Lviv), Liakhovsky V. I. (Poltava), Masna Z. Z. (Lviv), Mateshuk-Vatseba L.R. (Lviv), Nebesna Z. M. (Ternopil), Parkhomenko K. Yu. (Kharkiv), Pastukhova V. A. (Kiev), Pivtorak V. I. (Vinnytsia), Pikalyuk V. S. (Lutsk), Popadynets O. H. (Ivano-Frankivsk), Salutin R. V. (Kiev), Shapoval C. D. (Zaporizhzhia), Sikora V. Z. (Sumy), Topor B. M. (Chisinau, Moldova), Fedonyuk L. Ya. (Ternopil), Chernov V. C. (Nikolaev), Shepitko V. I. (Poltava), Skarban V. P. (Kiev), Trofimov M. V. (Dnipro), Vansovich V. Ye. (Odesa).

**Свідоцтво про державну реєстрацію –
серія КВ № 6031 від 05.04.2002 р.**

Журнал включений до баз даних:

**Ulrich`s Periodicals Directory, Google Scholar, Index Copernicus International,
Scientific Indexing Services, Infobase Index, Bielefeld Academic Search Engine,
International Committee of Medical Journal Editors,
Open Access Infrastructure for Research in Europe, WorldCat,
Наукова періодика України**

**Журнал «Клінічна анатомія та оперативна хірургія» –
наукове фахове видання України**

**(Постанова президії ВАК України від 14.10.2009 р., № 1-05/4), перереєстровано наказом
Міністерства освіти і науки України від 29 червня 2021 року № 735 щодо включення
до переліку наукових фахових видань України, категорія «Б»,
галузь науки «Медицина», спеціальність – 222**

Рекомендовано вченою радою
Буковинського державного медичного університету МОЗ України
(протокол № 13 від 25.05.2023 року)

ISSN 1727-0847

**Klinična anatomiâ ta operativna hirurgiâ (Print)
Clinical anatomy and operative surgery**

ISSN 1993-5897

**Klinična anatomiâ ta operativna hirurgiâ (Online)
Kliničeskaâ anatomiâ i operativnaâ hirurgiâ**

© Клінічна анатомія та оперативна хірургія, 2023

UDC 577.1.576.311.347.3

DOI: 10.24061/1727-0847.22.2.2023.24

M. V. Dikal, Ye. O. Ferenchuk, T. M. Bilous*, T. G. Kopchuk, V. M. Drachuk**, V. V. Bilous*****
*Departments of bioorganic and biological chemistry and clinical biochemistry (Head – Associate Professor N. P. Grigoriev); *pediatrics and children's infectious diseases (Head – Prof. O. K. Koloskova); **pharmacology (Head – Prof. I. I. Zamorskyi) of the higher education institution of the Bukovyna State Medical University of the Ministry of Health of Ukraine, Chernivtsi; ***Department of Physical Rehabilitation, Occupational Therapy and Pre-Medical Care (Head – Prof. L. G. Dotsyuk) of Yuri Fedkovich Chernivtsi National University, Chernivtsi*

BIOLOGICAL ROLE OF REACTIVE OXYGEN SPECIES IN MITOCHONDRIA

БІОЛОГІЧНА РОЛЬ АКТИВНИХ ФОРМ КИСНЮ В МІТОХОНДРІЯХ

Резюме. Стаття присвячена джерелам утворення вільних радикалів у мітохондріях та специфіці мітохондріальних антиоксидантних ензимів. Останні наукові дослідження підтверджують, що окислювальний стрес є причиною багатьох захворювань, зокрема, серцево-судинних, нейродегенеративних, захворювань нирок та печінки, запальних процесів, ракових новоутворень, розвитку цукрового діабету. Мітохондрії, як основні виробники АТФ, і водночас – генератори активних форм кисню (АФК), відіграють вирішальну роль у клітинному метаболізмі. Вони є важливою мішенню окисного пошкодження, яке може призвести до загибелі і мітохондрій, і клітини, оскільки пошкоджені мітохондрії продукуватимуть все більше АФК. Утворені вільні радикали можуть активувувати окислювально-відновні ензими, які беруть участь у захисних сигнальних шляхах, та безпосередньо впливати на життєздатність клітин. Проте мітохондріальна система містить антиоксидантні ензими і неферментативні компоненти з антиоксидантними властивостями, які допомагають контролювати баланс у оксидант-антиоксидантній системі організму. Окрім того, пошкодження мітохондрій і підвищений рівень вільних радикалів може бути одним із важливих біомаркерів для моніторингу прогресування різних захворювань.

Ключові слова: окислювальний стрес, активні форми кисню, антиоксидантна система, мітохондрії.

Oxidative stress plays an important role in the development and progress of different pathological processes. These free radical molecules are an assembly of reactive oxygen species (ROS) and reactive nitrogen species. Mitochondrial ROS are crucial for an organism's homeostasis. By regulation of signaling pathways, they activate the adaptation and protection behaviors of an organism under stress. The accumulation of ROS cause damage to DNA, proteins, and lipids, and other pathological processes [1, 2].

ROS are different products from the partial reduction of oxygen, including oxygen free radicals

(peroxyl [RO₂·], superoxide [(O₂⁻·), hydroxyl [OH·], alkoxy [RO·]), and some non-radical derivatives of oxygen (singlet oxygen (¹O₂), hydrogen peroxide (H₂O₂), and hypochlorous acid (HOCl)). Next ROS can be converted to reactive nitrogen species (peroxynitrite (ONOO⁻), nitric oxide (NO·), nitrogen dioxide (NO₂·)), and other oxides of nitrogen [3-5].

Hydroxyl radicals are short-lived, highly reactive, and contribute significantly to local organelle damage through protein modification. The intensive generation of ROS can be result of the action of p450 monooxygenase, mitochondrial oxidative

phosphorylation, nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, monoamine oxidase, lipoxygenase, xanthine oxidase, cyclooxygenase. As we know, mitochondria are not only the source of energy through oxidative phosphorylation on the inner membrane, but also process of mitochondrial oxidative phosphorylation is the main origin of free radicals. Free radicals a decrease in mitochondrial respiratory function, because they impair mitochondrial structure and function by increasing mitochondrial free radical production [6, 7].

The aim of article is a focus on the sources of free radicals in the mitochondria and specificity of mitochondrial antioxidant enzymes.

Mitochondrial energy generation.

Mitochondrial energy formation is first consummate in Krebs's cycle and submitted in ATP-form, nicotinamide adenine dinucleotide (NADH) and reduced flavin adenine dinucleotide (FADH₂). Next, oxidative phosphorylation is the primary energy process for conversion of the oxidoreduction energy of mitochondrial electron transport to the high energy phosphate bond ATP. Oxygen (O₂) is the terminal electron acceptor for cytochrome C oxidase of complex IV in the mitochondrial electron transport chain (ETC) catalyzed four electrons reduction of O₂ to water. Coenzyme Q (CoQ, ubiquinone) is an electron pool and a mediator of the electron transport between complex II and III (ubiquinone-cytochrome c reductase) with NADH- dehydrogenase (complex I). The major production site of O₂⁻ is reportedly complexes I and III. In general, I complex produces O₂⁻ on the matrix side of the inner membrane, whereas complex III-derived O₂⁻ is produced both towards the inner-membrane space and the matrix [8-10]. So, a decline in CoQ concentrations, activated reverse electron transfer, reducing of the electron transport rate, or inhibition of electron flow can cause high-energy electrons leaking from the ETC at complexes I, II, III, and IV to produce O₂⁻ [11].

The matrix contains the components of the tricarboxylic acid cycle and fatty acid β-oxidation pathway, as well as mitochondrial deoxyribonucleic acid (mtDNA). There is an opinion [6] that the mtDNA is one of critical targets for oxidative damage, because it can amplify the secondary generation of ROS. It is also noteworthy that self-amplification of the mitochondrial ROS generation can occur following ROS activation of mitochondrial permeability transition pore. Opening of the mitochondrial permeability transition pore is triggered and ROS can induce the simultaneous collapse of the mitochondrial membrane potential (Δψ) and a further increase in ROS generation by the electron transport chain [12].

In addition, mitochondrial respiration is ordinarily accompanied by low-level ROS production, but they can respond to elevated ROS concentrations by increasing their own ROS production – ROS-induced ROS release. The regenerative cycle of mitochondrial ROS formation and release apparently constitutes one of adaptive functions of the timely release from mitochondria of accumulated potentially toxic production of ROS [10].

Leakage of electrons from the electron transport chain can result in incomplete reduction of molecular oxygen to produce O₂⁻ which can damage heme moieties or enzymes with iron-sulfur centers such as aconitase ([4Fe-4S]→[3Fe-4S]⁺) to release ferrous ion (Fe⁺²). The Fe⁺² can subsequently react with H₂O₂ to generate hydroxyl radicals. Those superoxide radical anions can also react with NO[•] to form the damaging oxidant ONOO⁻, which is more reactive than either precursor. In turn, hydroxyl radical and nitric dioxide can be produced from ONOO⁻, and membrane lipid peroxidation and nitration of proteins on tyrosine residues are promoted. ONOO⁻ further damages the complexes I, II, and V as well as mitochondrial superoxide dismutase (SOD), glutathione peroxidase (GP_x), and aconitase. Some studies [13, 14] demonstrate that NO diffuses easily along its gradient into mitochondria and is also produced by mitochondria.

Mitochondrial membranes are mostly composed of protein and phospholipids, whose interdependence is critical for mitochondrial function. And fatty acids of the inner membrane are highly unsaturated. Therefore, ROS attack to the mitochondrial membrane lipid components results in lipid peroxidation, which alters the membrane potential [15, 16].

Enzymatic antioxidants and non-enzymatic mitochondrial components. Glutathione, CoQ, vitamin C, vitamin E, and lipoic acid are the non-enzymatic components of the antioxidant mitochondrial system. The enzymatic antioxidant mitochondrial system involves superoxide dismutase, glutathione peroxidase, catalase, glutathione-S-transferase (GST), glutathione reductase (GR), glutaredoxin, thioredoxin, thioredoxin reductase (TrxR). Some studies suggest [17, 18], that decreased levels of activity of mitochondrial SOD and GPx were associated with mitochondrial oxidative stress.

Mitochondria contain ~10-12 % of total glutathione quantity in a cell. Mitochondria can utilize glutathione in two ways: as a recyclable electron donor and as a consumable in conjugation reactions by glutathione-S-transferase. A large intramitochondrial pool of glutathione insures an efficient operation of the GST-based detoxifying

system. Reduced glutathione can scavenge superoxide and hydroxyl radical nonenzymatically or by serving as an electron-donating substrate to several enzymes involved in ROS-detoxification. In every case, glutathione is oxidized to glutathione disulfide that cannot be exported to cytosol and has to be reduced in the mitochondrial matrix. The reduction is catalyzed by glutathione reductase presented in the matrix of mitochondria.

There are three isoforms of superoxide dismutase in the vessel wall: copper-zinc SOD (CuZn-SOD or SOD₁), manganese SOD (Mn-SOD or SOD₂), and an EC-SOD is found in the extracellular space (SOD₃).

CuZn-SOD is located in the cytosol, nucleus, and intermembrane space of mitochondria. Manganese-dependent superoxide dismutase (Mn-SOD) has localisation in the mitochondrial matrix. This enzyme is a nuclear-encoded primary antioxidant and has place in the modulation of redox states. Enzyme contributes to the reduction of superoxide to H₂O₂. O₂^{•-} has a pro-inflammatory role and induces ONOO⁻ formation, lipid peroxidation, and recruitment of neutrophils to sites of inflammation. Mn-SOD (Fig. 1) can accelerate the reaction and rapidly convert O₂^{•-} to H₂O₂.





Fig. 1. The mechanism of formation reactive oxygen species in mitochondria

Mn-SOD can scavenge O₂^{•-} and therefore imitates anti-inflammatory agent. Mn-SOD suppresses ONOO⁻ production and tyrosine residue nitration and inhibits membrane lipid peroxidation and mDNA damage [19]. Additionally, Mn-SOD participates in the mitochondrial repair processes and has a role along with p53 in inhibition of mitochondrial DNA damage [20]. Copper, zinc-dependent superoxide dismutase is also found in the mitochondrial inter-membrane space, lysosomes, nuclei, and peroxisomes. Thus, Cu and Zn participate in the SOD enzymatic mechanisms play a significant role in oxidative balance [21, 22]. However, some O₂^{•-} escapes into the intermembrane space from the matrix side of the inner mitochondrial membrane, it can be partly catalyzed to H₂O₂ by Cu, Zn-SOD.

Selenium-containing glutathione peroxidase (GPx) has 8 multiple isoforms. GPx-1 is a major isoform localized in the cytoplasm and mitochondrial matrix [23] and metabolized H₂O₂ to oxygen and water. But the level of GPx-1 activity in mitochondria are very low, compared with cytoplasm. GPx-2 is the major

oxidative stress-inducible cellular isoform in the lungs. The isozyme GPx-3 is a selenoprotein, abundantly found in plasma. GPx-4 is membrane-associated that is found in the inter-membrane space of mitochondria, and is able of decreasing lipid hydroperoxides, alkyl peroxides, and fatty acid hydroperoxides with protect mitochondrial ATP generation. In some works [24, 25], GPx-4 has also been shown to repair mitochondrial oxidative damage, prevent transport of lipid peroxides and oxidative damage, and maintain the mitochondrial oxidative-phosphorylation.

Catalase is also an important antioxidant enzyme that catalyzes the conversion of H₂O₂ to H₂O. Enzyme consists of 4 subunits, each of which contains a ferric (Fe⁺³) heme group bound to its active site [26]. But deficiency of ferrum causes a significant decrease of catalase activity. This enzyme is found in peroxisomes and is also present in heart mitochondria. The presence of catalase in cardiomyocytes mitochondria may prevent excessive H₂O₂ from reaching the cytosol, eventually reacting with myoglobin [27-29].

The oxidation of superoxide-reduced cytochrome c by cytochrome c oxidase generates proton-motive force that mitochondria can use to produce ATP. And cytochrome loss can result in more ROS production from mitochondria [30].

Sources and regulation of mitochondrial ROS. A lot of researchers have an impression of mitochondrial dominance in cellular ROS production and therefore consider mitochondria as important therapeutic targets and potential regulators of life-time. The mitochondrial electron transport chain generates O_2 first at I and III complexes [2, 13, 26-28]. Complex III produces O_2 by autooxidation of the ubisemiquinone radical intermediate (QH), during the Q cycle in the complex, with the Q-site of the complex close to the intermembrane space being the principal site of O_2 production. The Q- site of complex III located close to the matrix side is less likely to react with oxygen and form O_2 since the Qi site firmly binds QH and stabilizes it. Selective inhibitors of the Qi portion of the cycle, such as antimycin B, prolong the lifetime of ubisemiquinone at the Q-site and hence result in excess release of O_2 . Conversely, inhibition of the proximal Q-site by compounds such as myxothiazol inhibits the formation of ubisemiquinone at the Q- site and thus reduces the production of O_2 [28-30].

Some authors also speculated that succinate dehydrogenase could be involved in ROS generation. Moreover, functional loss of Complex II can lead to the development of pathological conditions – carcinoma, obesity, and neurodegenerative diseases [31-34]. There are oxidoreductases that feed electrons to the coenzyme Q pool (NADH-dehydrogenase, glycerol-3-phosphate dehydrogenase, dihydroorotate dehydrogenase) etc. All of these might be able of activating the Q-site of ROS production.

Complex III has the power to release O_2 to both sides of the mitochondrial inner membrane, depending on the portion of the Q cycle involved. In contrast, complex I-derived O_2 appears released into the matrix. Although precise mechanisms of O_2

generation are largely unknown, it is suggested that complex I produces O_2 by reverse electron transfer from complex II upon succinate oxidation in the absence of NADH-linked substrates or in much lower amounts in the forward electron transfer from the NADH-linked substrates. It is suggested that an iron-sulfur cluster distal in the electron transfer route of the complex could be the site of electron leak and O_2 production. The primary ROS produced by mitochondria is O_2 , either in the matrix or the intermembrane space [35-37].

As a charged species, O_2 is not readily diffusible across mitochondrial membranes. But the mitochondrial penetration transition pore, containing the voltage-dependent mitochondrial anion channel, might serve as a channel for intermembranous mitochondrial O_2 to pass through the outer mitochondrial membrane and into the cytosol [24, 38]. Apparently, a more important mechanism for transmembrane move of reduced oxygen involves dismutation to H_2O_2 by superoxide dismutase. Once generated, the uncharged ROS H_2O_2 can easily act across the membrane.

Conclusions. The study of association between oxidative stress and mitochondrial dysfunction provides an opportunity for efficacy of therapies including maximization of anti-oxidant status. In addition, mitochondrial damage might provide an important biomarker for monitoring disease progression. Increased level of free radicals generated by damaged mitochondria cause oxidative damage and a significant disorder in metabolic processes; impair the flow of electrons along the electron transport chain; increase the mitochondrial membrane potential; decrease mitochondrial membrane fluidity and respiratory control ratios and cellular oxygen consumption; produce high levels of damage oxidants. NO produced locally within mitochondria may also be involved in the regulation of mitochondrial respiration and O_2 generation. However, the all reasons for this are unclear and need future investigation.

References

1. Zhang B, Pan C, Feng C, Yan C, Yu Y, Chen Z, et al. Role of mitochondrial reactive oxygen species in homeostasis regulation. *Redox Rep.* 2022 Dec;27(1):45-52. doi: 10.1080/13510002.2022.2046423.
2. Mailloux RJ. An Update on Mitochondrial Reactive Oxygen Species Production. *Antioxidants (Basel).* 2020 Jun 2;9(6):472. doi: 10.3390/antiox9060472.
3. Gerdes HJ, Yang M, Heisner JS, Camara AKS, Stowe DF. Modulation of peroxynitrite produced via mitochondrial nitric oxide synthesis during Ca^{2+} and succinate-induced oxidative stress in cardiac isolated mitochondria. *Biochim Biophys Acta Bioenerg.* 2020 Dec 1;1861(12):148290. doi: 10.1016/j.bbabi.2020.148290.
4. Islam MN, Rauf A, Fahad FI, Emran TB, Mitra S, Olatunde A, et al. Superoxide dismutase: an updated review on its health benefits and industrial applications. *Crit Rev Food Sci Nutr.* 2022;62(26):7282-300. doi: 10.1080/10408398.2021.1913400.

5. Gyu Choi T, Soo Kim S. *Physiological Functions of Mitochondrial Reactive Oxygen Species [Internet]. Free Radical Medicine and Biology. IntechOpen; 2020. Available from: <http://dx.doi.org/10.5772/intechopen.88386>*
6. Rodríguez-Nuevo A, Torres-Sánchez A, Duran JM, De Guirior C, Martínez-Zamora MA, Böke E. *Oocytes maintain ROS-free mitochondrial metabolism by suppressing complex I. Nature. 2022 Jul;607(7920):756-61. doi: 10.1038/s41586-022-04979-5.*
7. Andrés CMC, Pérez de la Lastra JM, Juan CA, Plou FJ, Pérez-Lebeña E. *Chemistry of Hydrogen Peroxide Formation and Elimination in Mammalian Cells, and Its Role in Various Pathologies. Stresses. 2022;2(3):256-74. doi:10.3390/stresses2030019.*
8. Chazelas P, Steichen C, Favreau F, Trouillas P, Hannaert P, Thuillier R, et al. *Oxidative Stress Evaluation in Ischemia Reperfusion Models: Characteristics, Limits and Perspectives. Int J Mol Sci. 2021 Feb 27;22(5):2366. doi: 10.3390/ijms22052366.*
9. Sies H. *Hydrogen peroxide as a central redox signaling molecule in physiological oxidative stress: Oxidative eustress. Redox Biol. 2017 Apr;11:613-9. doi: 10.1016/j.redox.2016.12.035.*
10. Hyslop PA, Chaney MO. *Mechanism of GAPDH Redox Signaling by H₂O₂ Activation of a Two-Cysteine Switch. Int J Mol Sci. 2022 Apr 21;23(9):4604. doi: 10.3390/ijms23094604.*
11. Zou L, Linck V, Zhai YJ, Galarza-Paez L, Li L, Yue Q, et al. *Knockout of mitochondrial voltage-dependent anion channel type 3 increases reactive oxygen species (ROS) levels and alters renal sodium transport. J Biol Chem. 2018 Feb 2;293(5):1666-75. doi: 10.1074/jbc.M117.798645.*
12. Kuo CL, Chou HY, Chiu YC, Cheng AN, Fan CC, Chang YN, et al. *Mitochondrial oxidative stress by Lon-PYCR1 maintains an immunosuppressive tumor microenvironment that promotes cancer progression and metastasis. Cancer Lett. 2020 Apr 1;474:138-50. doi: 10.1016/j.canlet.2020.01.019.*
13. Cadenas S. *Mitochondrial uncoupling, ROS generation and cardioprotection. Biochim Biophys Acta Bioenerg. 2018 Sep;1859(9):940-50. doi: 10.1016/j.bbabi.2018.05.019.*
14. Zhou J, Li A, Li X, Yi J. *Dysregulated mitochondrial Ca²⁺ and ROS signaling in skeletal muscle of ALS mouse model. Arch Biochem Biophys. 2019 Mar 15;663:249-58. doi: 10.1016/j.abb.2019.01.024.*
15. Jadiya P, Kolmetzky DW, Tomar D, Di Meco A, Lombardi AA, Lambert JP, et al. *Impaired mitochondrial calcium efflux contributes to disease progression in models of Alzheimer's disease. Nat Commun. 2019 Aug 29;10(1):3885. doi: 10.1038/s41467-019-11813-6.*
16. Marchi S, Guilbaud E, Tait SWG, Yamazaki T, Galluzzi L. *Mitochondrial control of inflammation. Nat Rev Immunol. 2023 Mar;23(3):159-73. doi: 10.1038/s41577-022-00760-x.*
17. Dontaine J, Bouali A, Daussin F, Bultot L, Vertommen D, Martin M, et al. *The intra-mitochondrial O-GlcNAcylation system rapidly modulates OXPHOS function and ROS release in the heart. Commun Biol. 2022 Apr 12;5(1):349. doi: 10.1038/s42003-022-03282-3.*
18. Cheng G, Zielonka M, Dranka B, Kumar SN, Myers CR, Bennett B, et al. *Detection of mitochondria-generated reactive oxygen species in cells using multiple probes and methods: Potentials, pitfalls, and the future. J Biol Chem. 2018 Jun 29;293(26):10363-80. doi: 10.1074/jbc.RA118.003044.*
19. Kalyanaraman B, Cheng G, Hardy M, Ouari O, Bennett B, Zielonka J. *Teaching the basics of reactive oxygen species and their relevance to cancer biology: Mitochondrial reactive oxygen species detection, redox signaling, and targeted therapies. Redox Biol. 2018 May;15:347-62. doi: 10.1016/j.redox.2017.12.012.*
20. Idelchik MDPS, Begley U, Begley TJ, Melendez JA. *Mitochondrial ROS control of cancer. Semin Cancer Biol. 2017 Dec;47:57-66. doi: 10.1016/j.semcancer.2017.04.005.*
21. Tan EP, McGreal SR, Graw S, Tessman R, Koppel SJ, Dhakal P, et al. *Sustained O-GlcNAcylation reprograms mitochondrial function to regulate energy metabolism. J Biol Chem. 2017 Sep 8;292(36):14940-62. doi: 10.1074/jbc.M117.797944.*
22. Bernardi P, Carraro M, Lippe G. *The mitochondrial permeability transition: Recent progress and open questions. FEBS J. 2022 Nov;289(22):7051-74. doi: 10.1111/febs.16254.*
23. Smith EF, Shaw PJ, De Vos KJ. *The role of mitochondria in amyotrophic lateral sclerosis. Neurosci Lett. 2019 Sep 25;710:132933. doi: 10.1016/j.neulet.2017.06.052.*
24. Angelova PR, Esteras N, Abramov AY. *Mitochondria and lipid peroxidation in the mechanism of neurodegeneration: Finding ways for prevention. Med Res Rev. 2021 Mar;41(2):770-84. doi: 10.1002/med.*

25. Ulgherait M, Chen A, McAllister SF, Kim HX, Delventhal R, Wayne CR, et al. Circadian regulation of mitochondrial uncoupling and lifespan. *Nat Commun.* 2020 Apr 21;11(1):1927. doi: 10.1038/s41467-020-15617-x.
26. Otera H, Ishihara N, Mihara K. New insights into the function and regulation of mitochondrial fission. *Biochim Biophys Acta.* 2013 May;1833(5):1256-68. doi: 10.1016/j.bbamcr.2013.02.002.
27. Cui Y, Pan M, Ma J, Song X, Cao W, Zhang P. Recent progress in the use of mitochondrial membrane permeability transition pore in mitochondrial dysfunction-related disease therapies. *Mol Cell Biochem.* 2021 Jan;476(1):493-506. doi: 10.1007/s11010-020-03926-0.
28. Zhunina OA, Yabbarov NG, Grechko AV, Starodubova AV, Ivanova E, Nikiforov NG, et al. The Role of Mitochondrial Dysfunction in Vascular Disease, Tumorigenesis, and Diabetes. *Front Mol Biosci.* 2021 May 7;8:671908. doi: 10.3389/fmolb.2021.671908.
29. Gnaiger E. Mitochondrial pathways and respiratory control. An introduction to OXPHOS analysis. *Bioenerg Commun.* 2020;2. doi:10.26124/bec:2020-0002.
30. Mori K, Uchida T, Yoshie T, Mizote Y, Ishikawa F, Katsuyama M, Shibamura M. A mitochondrial ROS pathway controls matrix metalloproteinase 9 levels and invasive properties in RAS-activated cancer cells. *FEBS J.* 2019 Feb;286(3):459-78. doi: 10.1111/febs.14671.
31. Hadrava Vanova K, Kraus M, Neuzil J, Rohlena J. Mitochondrial complex II and reactive oxygen species in disease and therapy. *Redox Rep.* 2020 Dec;25(1):26-32. doi: 10.1080/13510002.2020.1752002.
32. Dalla Pozza E, Dando I, Pacchiana R, Liboi E, Scupoli MT, Donadelli M, et al. Regulation of succinate dehydrogenase and role of succinate in cancer. *Semin Cell Dev Biol.* 2020 Feb;98:4-14. doi: 10.1016/j.semcdb.2019.04.013.
33. Li J, Liang N, Long X, Zhao J, Yang J, Du X. et al. SDHC-related deficiency of SDH complex activity promotes growth and metastasis of hepatocellular carcinoma via ROS/NFκB signaling. *Cancer Lett.* 2019 Oct 1;461:44-55. doi: 10.1016/j.canlet.2019.07.001.
34. Ngo DTM, Sverdlov AL, Karki S, Macartney-Coxson D, Stubbs RS, Farb MG, et al. Oxidative modifications of mitochondrial complex II are associated with insulin resistance of visceral fat in obesity. *Am J Physiol Endocrinol Metab.* 2019 Feb 1;316(2): E168-E177. doi: 10.1152/ajpendo.00227.2018.
35. Sadler JC, Currin A, Kell DB. Ultra-high throughput functional enrichment of large monoamine oxidase (MAO-N) libraries by fluorescence activated cell sorting. *Analyst.* 2018 Sep 24;143(19):4747-4755. doi: 10.1039/c8an00851e.
36. Bock FJ, Tait SWG. Mitochondria as multifaceted regulators of cell death. *Nat Rev Mol Cell Biol.* 2020 Feb;21(2):85-100. doi: 10.1038/s41580-019-0173-8.
37. Cheung EC, Vousden KH. The role of ROS in tumour development and progression. *Nat Rev Cancer.* 2022;22:280-97. doi: 10.1038/s41568-021-00435-0.
38. Winterbourn CC. Hydrogen peroxide reactivity and specificity in thiol-based cell signalling. *Biochem. Soc. Trans.* 2020;48:745-54.

BIOLOGICAL ROLE OF REACTIVE OXYGEN SPECIES IN MITOCHONDRIA

Abstract. This article focuses on the sources of free radicals in the mitochondria and the specificity of mitochondrial antioxidant enzymes. In recent years, oxidative stress is associated with many human diseases, including: cardiovascular, neurodegenerative, and kidney and liver disorders, a wide range of inflammatory-related diseases, cancer, diabetes mellitus. Mitochondria, as the major ATP producer and the major reactive oxygen species (ROS) and antioxidant producer exert a crucial role within the cell metabolism. And mitochondria represent an important target for oxidative damage, which can lead to the death of mitochondria and cell, because damaged mitochondria produce increasingly more (ROS). Produced ROS often activate local pools of redox-sensitive enzymes of protective signaling pathways and may directly influence cell viability. However, there are also enzymatic and non-enzymatic components of the antioxidant mitochondrial system that help in controlling the oxidant-antioxidant system. Moreover, mitochondrial damage and increased level of free radicals might provide one of the important biomarkers for monitoring different disease progression.

Key words: oxidative stress, reactive oxygen species, antioxidant system, mitochondria.

Відомості про авторів:

Дікал Мар'яна Вікторівна – кандидат медичних наук, доцентка кафедри біоорганічної і біологічної хімії та клінічної біохімії закладу вищої освіти Буковинського державного медичного університету, м. Чернівці;

Ференчук Єлена Олександрівна – кандидат медичних наук, асистентка кафедри біоорганічної і біологічної хімії та клінічної біохімії закладу вищої освіти Буковинського державного медичного університету, м. Чернівці;

Білоус Тетяна Михайлівна – доктор медичних наук, професорка кафедри педіатрії та дитячих інфекційних хвороб закладу вищої освіти Буковинського державного медичного університету, м. Чернівці;

Копчук Тамара Григорівна – кандидат медичних наук, доцентка кафедри фармакології закладу вищої освіти Буковинського державного медичного університету, м. Чернівці;

Драчук Віра Михайлівна – кандидат фармацевтичних наук, доцентка кафедри фармакології закладу вищої освіти Буковинського державного медичного університету, м. Чернівці;

Білоус Володимир Володимирович – викладач кафедри фізичної реабілітації, ерготерапії та домедичної допомоги Чернівецького національного університету імені Юрія Федьковича, м. Чернівці.

Information about the authors:

Dikal Mariana V. – Candidate of Medical Sciences, Associate Professor of the Department of Bioorganic and Biological Chemistry and Clinical Biochemistry of the Bukovinian State Medical University, Chernivtsi;

Ferenchuk Yelena OI. – Candidate of Medical Sciences, Assistant of the Department of Bioorganic and Biological Chemistry and Clinical Biochemistry of the Bukovinian State Medical University, Chernivtsi;

Bilous Tetiana M. – Doctor of Medical Sciences, Professor of the Department of Paediatrics and Children Infectious Diseases of the Bukovinian State Medical University, Chernivtsi;

Kopchuk Tamara G. – Candidate of Medical Sciences, Associate Professor Department of Pharmacology of the Bukovinian State Medical University, Chernivtsi;

Drachuk Vira M. – Candidate of Pharmaceutical Sciences, Associate Professor Department of Pharmacology of the Bukovinian State Medical University, Chernivtsi;

Bilous Volodymyr Vol. – Teacher of the Department of Physical Rehabilitation, Occupational Therapy and Premedical Care, Yuriy Fedkovych Chernivtsi National University, Chernivtsi.

Надійшла 02.05.2023 р.

Рецензент – проф. М. К. Братенко (Чернівці)